Table 2.

List of studies combining antiangiogenic agents with oncolytic viruses.

	Oncolytic Virus used	Type of virus	Tumor model	Treatment strategy	Efficacy	Reference
Avastin
1	Dl922-947	E1A deleted Adenovirus	Anaplastic thyroid carcinomas in athymic nude mice	Avastin (i.p.) every 5th day and OV twice a week for 4 weeks	Co-treatment group enhanced efficacy over single agent alone	Libertini et al. Clin Cancer Res 2008;14:6505–14
2	Ad5/3-Δ24	Ad5 virus with E1 gene with 24 bp deltion, and serotype 3 knob	Peritoneal disseminated Renal Cell cancer in SCID mice	Avastin: i.p. once a week for 5 weeks and OV: i.p. on days 7, 14, and 21 post tumor implant.	No enhancement over OV alone	Guse et al. Mol Cancer Ther 2007;6:2728–32
3	Ad5-Δ24RGD	Ad5 virus with E1 gene with 24 bp deltion, RGD motif in H1 loop of knob protein	Peritoneal disseminated Renal Cell cancer in SCID mice	Avastin: i.p. once a week for 5 weeks and OV: i.p. on days 7, 14, and 21 post tumor implant.	No enhancement over OV alone	Guse et al. Mol Cancer Ther 2007;6:2728–32
4	Ad5.pk7-Δ24	Ad5 virus with E1 gene with 24 bp deltion, and 7 lysine residues at C terminus of fiber	Peritoneal disseminated Renal Cell cancer in SCID mice	Avastin: i.p. once a week for 5 weeks and OV: i.p. on days 7, 14, and 21 post tumor implant.	No enhancement over OV alone	Guse et al. Mol Cancer Ther 2007;6:2728–32
5	GLV-1h68	Renilla luciferase, GFP, and fusion, β-galactosidase, and β-glucuronidase expressing VV	s.c Pancreatic cancer cells in mice	Avastin: twice a week for 5 weeks 13 days post OV treatment; OV: single dose i.v	Co treatment group enhanced efficacy over single agent alone.	Frentzen et al. Proc Natl Acad Sci USA 2009;106:12915–20
Thrombospondin 1 peptide
5	G207	HSV-1 deleted for ICP34.5 and disrupted for ICP6	s.c glioma in nude mice	TSR peptide: i.p. daily days 1–27. OV: on days 2 and 5.	Co treatment group enhanced efficacy over single agent alone.	Aghi et al. Cancer Res 2007;67:440–4
6	G47Δ	HSV-1 deleted for ICP34.5 and disrupted for ICP6, and deted for α47.	s.c glioma in nude mice	TSR peptide: i.p. daily days 1–27. OV: on days 2 and 5.	No enhancement over OV alone	Aghi et al. Cancer Res 2007;67:440–4
Trichostatin A
7	G47Δ	HSV-1 deleted for ICP34.5 and disrupted for ICP6, and deted for α47.	s.c glioma in nude mice	TSA:i.p. daily for twelve days; OV: i.t on days 1, and 4.	Co treatment group enhanced efficacy over single agent alone.	Liu et al. Mol Ther 2008;16:1041–7
Cilengitide
8	hrR3	HSV-1 deleted for ICP34.5 and disrupted for ICP6, and deted for α47.	i.c rat glioma in rats	Cilengitide: i.t on day 3; OV: i.t day 7	Co treatment group enhanced efficacy over single agent alone.	Kurozumi et al. J Natl Cancer Inst. 2007;99:1768–81
Thalidomide
9		HSV-1 +/− forICP34.5 and mutant gB and gK.	s.c 4T1 tumors in mice	Thalidomide: orally in chow from day 4; OV: i.t three times	Co treatment group enhanced efficacy over single agent alone.	Israyelyan et al. Cancer Chemother Pharmacol 2009;64:1201–10

Abbreviations; i.v: intra venous; s.c: sub cutaneous; i.p: intra peritoneal; i.c: intra cranial; Ad: Adenovirus; VV: Vaccinia virus